Investing.com -- Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock gained 3.7% on Thursday after the company announced it received a new patent in South Korea for its lead compound Aramchol in combination with Rezdiffra for treating metabolic dysfunction-associated steatohepatitis (MASH).
The patent covers the use of Aramchol in combination with Rezdiffra (resmetirom) for treating MASH and liver fibrosis. This South Korean patent adds to similar protections already granted in the United States, Europe, Canada, and other jurisdictions, extending Aramchol’s patent protection worldwide until July 2042.
Galmed described Aramchol as a "first-in-class, Phase 3 ready, drug candidate" that demonstrated robust fibrosis improvement in advanced clinical studies. The company emphasized that Aramchol’s safety profile makes it suitable for combination with other MASH treatments.
"This patent grant comes at a pivotal moment in the NASH/MASH field, as the industry shifts toward combination therapies to address this complex disease," said Allen Baharaff, CEO of Galmed Pharmaceuticals. He noted that with the "limited mild to moderate efficacy demonstrated by monotherapies," combination MASH clinical studies are becoming necessary.
The patent strengthens Galmed’s position in MASH combination therapy development at a time when commercial interest in treatments for the condition is increasing. Galmed is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver, cardiometabolic diseases, and GI oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
